Hillhouse Capital Management Ltd. purchased a new stake in UROGEN PHARMA (NASDAQ:URGN) during the second quarter, according to its most recent filing with the SEC. The fund purchased 352,300 shares of the company’s stock, valued at approximately $6,363,000. Hillhouse Capital Management Ltd. owned about 15.28% of UROGEN PHARMA as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in URGN. Alps Advisors Inc. purchased a new stake in UROGEN PHARMA in the 2nd quarter worth $195,000. Jennison Associates LLC bought a new stake in shares of UROGEN PHARMA in the second quarter worth about $3,168,000. Menora Mivtachim Holdings LTD. purchased a new stake in shares of UROGEN PHARMA in the second quarter worth about $2,331,000. Spark Investment Management LLC purchased a new stake in shares of UROGEN PHARMA in the second quarter worth about $856,000. Finally, LLBH Private Wealth Management LLC purchased a new stake in shares of UROGEN PHARMA in the second quarter worth about $695,000. Institutional investors own 36.06% of the company’s stock.

A number of research firms have issued reports on URGN. Oppenheimer Holdings, Inc. set a $32.00 price objective on UROGEN PHARMA and gave the stock a “buy” rating in a research note on Monday, August 14th. Zacks Investment Research downgraded UROGEN PHARMA from a “buy” rating to a “hold” rating in a research report on Friday, August 18th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $26.00.

Shares of UROGEN PHARMA (NASDAQ URGN) traded down 4.75% on Wednesday, hitting $30.45. 25,342 shares of the company were exchanged. The firm’s 50-day moving average is $25.81 and its 200-day moving average is $20.30. UROGEN PHARMA has a 52-week low of $13.01 and a 52-week high of $33.77. The stock’s market capitalization is $396.15 million.

COPYRIGHT VIOLATION WARNING: This story was reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at http://www.mareainformativa.com/hillhouse-capital-management-ltd-purchases-new-holdings-in-urogen-pharma-urgn/115460/.

UROGEN PHARMA Company Profile

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UROGEN PHARMA (NASDAQ:URGN).

Institutional Ownership by Quarter for UROGEN PHARMA (NASDAQ:URGN)

Receive News & Stock Ratings for UROGEN PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UROGEN PHARMA and related stocks with our FREE daily email newsletter.